Table 3.
Antifibrinolytics Literature Review.
| Publication | Study Design | Patients (Controls) | Mean ΔEBL (cm3) | Complications Odds Ratio |
|---|---|---|---|---|
| Tranexamic acid (TXA) | ||||
| Elwatidy et al, 2008 | Double-blinded RCT | 64 (32) | −273 | No data |
| Wong et al, 2008 | Double-blinded RCT | 147 (74) | −397* | 1.01 |
| Farrokhi et al, 2011 | Double-blinded RCT | 76 (38) | −67 | No data |
| Tsutsumimoto et al, 2011 | Nonblinded RCT | 40 (20) | −14.3 | No data |
| Yagi et al, 2012 | Retrospective cohort study | 106 (63) | −466 | No complications |
| Wang et al, 2013 | Nonblinded RCT | 60 (30) | −28.4 | No data |
| Raksakietisak et al, 2015 | Double-blinded RCT | 78 (39) | −250 | No data |
| Colomina et al, 2017 | Double-blinded RCT | 95 (51) | −332* | 2.45 |
| Shi et al, 2017 | Double-blinded RCT | 96 (46) | −85* | 0.30 |
| ∊-Aminocaproic acid (EACA) | ||||
| Urban et al, 2001 | Nonblinded RCT | 35 (18) | No data | 0.31 |
| Florintino-Pineda et al, 2004 | Double-blinded RCT | 36 (17) | −99 | No complications |
| Berenholtz et al, 2009 | Double-blinded RCT | 91 (50) | −335 | 0.37 |
| TXA and EACA | ||||
| Peters et al, 2015 | Double-blinded RCT | 32 (13) | No data | 2.19 |
| Lu et al, 2018 | Meta-analysis of 12 RCTs | 937 (465) | −127 | 0.62 |
Abbreviations: EBL, intraoperative estimated blood loss; RCT, randomized controlled trial.
*P < .05.